Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified
Conditions
Interventions
Intervention1: Escitalopram: 10 mg OD for 6-12 weeks
Control Intervention1: NIL: NIL
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult males or females aged 18 to 65 with the diagnosis of Major Depressive Disorder (MDD) 2. Patients who are drug naive or have started on antidepressant therapy for less than 2 weeks
Exclusion criteria
Exclusion criteria: Patients with any known neurological or any systemic disorders known to cause major depressive disorder Patients with any other psychiatric illness and substance use disorders Pregnant and lactating women Patients not willing to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean serum orexin Timepoint: At baseline and 6-12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Orexin and BDNF gene variants Mean Montgomery Asberg Depression rating score Mean PSQI sleep score Mean MoCA score Mean serum orexin Mean serum BDNF Metabolomic profile mean metabolite levelsTimepoint: Week 1 | — |
Countries
India
Contacts
Public ContactDr KH Reeta
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed